NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression

Molecular Endocrinology

Volumn 28, Issue 6, 2014, Pages 949-964

  Grabowska, Magdalena M ^a   Elliott, Amicia D ^a   DeGraff, David J ^c   Anderson, Philip D ^d   Anumanthan, Govindaraj ^a   Yamashita, Hironobu ^a   Sun, Qian ^a   Friedman, David B ^b   Hachey, David L ^e   Yu, Xiuping ^a   Sheehan, Jonathan H ^b   Ahn, Jung Mo ^f   Raj, Ganesh V ^g   Piston, David W ^a   Gronostajski, Richard M ^h   Matusik, Robert J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e SALISBURY UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; NUCLEAR FACTOR I; PROBASIN; PROSTATE SPECIFIC ANTIGEN; ANDROGEN BINDING PROTEIN; FOXA1 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE; GENE EXPRESSION REGULATION; GENE TARGETING; GENOMICS; HUMAN; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE SPECIFIC GENE; PROTEIN BINDING; PROTEIN INTERACTION; SEQUENCE ANALYSIS; ANTIBODY SPECIFICITY; CONSENSUS SEQUENCE; ENHANCER REGION; GENETIC TRANSCRIPTION; GENETICS; HELA CELL LINE; MALE; METABOLISM; PROSTATE; PROTEIN ANALYSIS;

ANDROGEN-BINDING PROTEIN; BASE SEQUENCE; BINDING SITES; CONSENSUS SEQUENCE; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION; HELA CELLS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; NFI TRANSCRIPTION FACTORS; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROSTATE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 84901917031     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2013-1213     Document Type: Article

References (80)

1. Cunha GR, Lung B, Reese B. Glandular epithelial induction by embryonic mesenchyme in adult bladder epithelium of BALB/c mice. Invest Urol. 1980;17:302-304.
2. Cunha GR, Lung B. The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool. 1978; 205:181-193.
3. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev. 1987;8:338-362.
4. Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013;182:1942-1949.
5. Gierer A. Molecular models and combinatorial principles in cell differentiation and morphogenesis. Cold Spring Harbor Symp Quant Biol. 1974;38:951-961.
6. Matusik RJ, Jin RJ, Sun Q, et al. Prostate epithelial cell fate. Differentiation. 2008;76:682-698.
7. Zhang J, Gao N, DeGraff DJ, et al. Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression. Prostate. 2010;70:934-951.
8. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7:271-277.
9. Gao N, Zhang J, Rao MA, et al. The role of hepatocyte nuclear factor-3α (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol. 2003;17: 1484-1507.
10. Gao N, Ishii K, Mirosevich J, et al. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development. 2005;132:3431-3443.
11. DeGraff DJ, Yu X, Sun Q, et al. The role of Foxa proteins in the regulation of androgen receptor activity. In: Tindall DJ, Mohler JL, eds. Androgen Action in Prostate Cancer. New York, NY: Springer; 2009:587-615.
12. Friedman JR, Kaestner KH. The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci. 2006;63: 2317-2328.
13. DeGraff DJ, Clark PE, Cates JM, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7:e36669.
14. Gerhardt J, Montani M, Wild P, et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol. 2012;180:848-861.
15. Mirosevich J, Gao N, Matusik RJ. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate. 2005; 62:339-352.
16. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 2002;9: 279-289.
17. Robinson JLL, Hickey TE, Warren AY, et al. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype [published online ahead of print December 2, 2013]. Oncogene. doi: 10.1038/onc.2013.508.
18. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression and role of Foxa proteins in prostate cancer. Prostate. 2006;66:1013-1028.
19. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487: 239-243.
20. Sahu B, Laakso M, Ovaska K, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011;30:3962-3976.
21. Sahu B, Laakso M, Pihlajamaa P, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013;73:1570-1580.
22. Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguère V. From the cover: Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005;102:11651-11656.
23. Belikov S, Åstrand C, Wrange Ö. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptorregulated promoter. Mol Cell Biol. 2009;29:5413-5425.
24. Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33-43.
25. Wang D, Garcia-Bassets I, Benner C, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature. 2011;474:390-394.
26. Murtagh J, Martin F, Gronostajski RM. The nuclear factor I (NFI) gene family in mammary gland development and function. J Mammary Gland Biol Neoplasia. 2003;8:241-254.
27. Kruse U, Sippel AE. Transcription factor nuclear factor I proteins form stable homo-and heterodimers. FEBS Lett. 1994;348:46-50.
28. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. Transcriptomes of human prostate cells. BMC Genomics. 2006;7:92.
29. Wong YW, Schulze C, Streichert T, Gronostajski RM, Schachner M, Tilling T. Gene expression analysis of nuclear factor I-A deficient mice indicates delayed brain maturation. Genome Biol. 2007; 8:R72.
30. Gründer A, Ebel TT, Mallo M, et al. Nuclear factor I-B (Nfib) deficient mice have severe lung hypoplasia. Mech Dev. 2002;112: 69-77.
31. Steele-Perkins G, Butz KG, Lyons GE, et al. Essential role for NFIC/ CTF transcription-replication factor in tooth root development. Mol Cell Biol. 2003;23:1075-1084.
32. Driller K, Pagenstecher A, Uhl M, et al. Nuclear factor I X deficiency causes brain malformation and severe skeletal defects. Mol Cell Biol. 2007;27:3855-3867.
33. Campbell CE, Piper M, Plachez C, et al. The transcription factor Nfix is essential for normal brain development. BMC Dev Biol. 2008;8:52.
34. Norquay LD, Yang X, Jin Y, Detillieux KA, Cattini PA. Hepatocyte nuclear factor-3α binding at P sequences of the human growth hormone locus is associated with pituitary repressor function. Mol Endocrinol. 2006;20:598-607.
35. Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J Steroid Biochem Mol Biol. 1996;59:243-250.
36. Messina G, Biressi S, Monteverde S, et al. Nfix regulates fetalspecific transcription in developing skeletal muscle. Cell. 2010;140: 554-566.
37. Bachurski CJ, Yang GH, Currier TA, Gronostajski RM, Hong D. Nuclear factor I/thyroid transcription factor 1 interactions modulate surfactant protein C transcription. Mol Cell Biol. 2003;23: 9014-9024.
38. Sun Q, Yu X, Degraff DJ, Matusik RJ. Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Mol Endocrinol. 2009;23:2038-2047.
39. Kang Z, Jänne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol. 2004;18:2633-2648.
40. Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17:443-454.
41. Leinonen R, Sugawara H, Shumway M. The sequence read archive. Nucleic Acids Res. 2011;39:D19-D21.
42. Andrews S. FastQC: a quality control tool for high throughput sequence data. Babraham Institute, 2010. http://www.bioinformatics. babraham.ac.uk/projects/fastqc/. Accessed October 30, 2012.
43. Langmead B, Trapnell C, Pop M, Salzberg S. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.
44. Heinz S, Benner C, Spann N, et al. Simple combinations of lineagedetermining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38: 576-589.
45. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA. 2004;101:4758-4763.
46. Clark KL, Halay ED, Lai E, Burley SK. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 1993;364:412-420.
47. Shi Y, Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling. Cell. 1998;94:585-594.
48. Ginalski K, Elofsson A, Fischer D, Rychlewski L. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics. 2003;19:1015-1018.
49. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comp Chem. 2004;25:1605-1612.
50. Macke T, Case DA. Modeling unusual nucleic acid structures. In: Leontes NB, SantaLucia J Jr, eds. Molecular Modeling of Nucleic Acids, Washington, DC: American Chemical Society; 1998:379-393.
51. Stroud JC. Automation of Making Nucleic Acid Helices by NAB. http://structure.usc.edu/make-na/. Updated August 3, 2013. Accessed August 7, 2011.
52. Darne CH, Morel L, Claessens F, et al. Ubiquitous transcription factors NF1 and Sp1 are involved in the androgen activation of the mouse vas deferens protein promoter. Mol Cell Endocrinol. 1997; 132:13-23.
53. Kuwahara S, Ikei A, Taguchi Y, et al. PSPC1, NONO, and SFPQ are expressed in mouse Sertoli cells and may function as coregulators of androgen receptor-mediated transcription. Biol Reprod 2006;75:352-359.
54. Dong X, Sweet J, Challis JR, Brown T, Lye SJ. Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol Cell Biol. 2007;27:4863-4875.
55. Salton M, Lerenthal Y, Wang SY, Chen DJ, Shiloh Y. Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response. Cell Cycle. 2010;9:1568-1576.
56. Lemon B, Inouye C, King DS, Tjian R. Selectivity of chromatinremodelling cofactors for ligand-activated transcription. Nature. 2001;414:924-928.
57. Shank LC, Kelley JB, Gioeli D, et al. Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro. J Biol Chem. 2008;283:10568-10580.
58. Jia L, Berman BP, Jariwala U, et al. Genomic androgen receptoroccupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One. 2008;3:e3645.
59. Yeung LH, Read JT, Sorenson P, Nelson CC, Jia W, Rennie PS. Identification and characterization of a prostate-specific androgenindependent protein-binding site in the probasin promoter. Biochem J. 2003;371:843-855.
60. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002;9:601-610.
61. Piston DW, Kremers GJ. Fluorescent protein FRET: the good, the bad and the ugly. Trends Biochem Sci. 2007;32:407-414.
62. Tan PY, Chang CW, Chang KR, Wansa KD, Sung WK, Cheung E. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol. 2012;32: 399-414.
63. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 2007;27:380-392.
64. Espinás ML, Roux J, Pictet R, Grange T. Glucocorticoids and protein kinase A coordinately modulate transcription factor recruitment at a glucocorticoid-responsive unit. Mol Cell Biol. 1995;15: 5346-5354.
65. Lupien M, Eeckhoute J, Meyer CA, et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008;132:958-970.
66. Biddie SC, John S, Sabo PJ, et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell. 2011;43:145-155.
67. Brüggemeier U, Rogge L, Winnacker EL, Beato M. Nuclear factor I acts as a transcription factor on the MMTV promoter but competes with steroid hormone receptors for DNA binding. EMBO J. 1990;9:2233-2239.
68. Crawford DR, Leahy P, Hu CY, et al. Nuclear factor I regulates expression of the gene for phosphoenolpyruvate carboxykinase (GTP). J Biol Chem. 1998;273:13387-13390.
69. Sharma NL, Massie CE, Ramos-Montoya A, et al. The androgen receptor induces a distinct transcriptional program in castrationresistant prostate cancer in man. Cancer Cell. 2013;23:35-47.
70. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009;103:1574-1580.
71. DeGraff DJ, Grabowska MM, Case T, et al. Foxa1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype [published online May 19, 2014]. Lab Invest. 2014. doi:10.1038/labinvest.2014.64.
72. Helpap B, Köllermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch. 1999;434:385-391.
73. Dooley AL, Winslow MM, Chiang DY, et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 2011;25:1470-1475.
74. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006;66:7889-7898.
75. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:1187-1197.
76. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437-1446.
77. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-992.
78. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309-1322.
79. Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab. 2000;11:281-285.
80. Mason S, Piper M, Gronostajski RM, Richards LJ. Nuclear factor one transcription factors in CNS development. Mol Neurobiol. 2009;39:10-23.